AIM: To assess synaptic density and to investigate the potential relationship of regional synaptic loss with motor and non-motor symptoms and with disease progression in the human brain in vivo in patients with PD. DESIGN: We will include 30 PD patients and 20 healthy controls. All subjects will undergo a clinical examination, with comprehensive assessment of motor and non-motor symptoms, and imaging evaluation consisting of 11C-UCB-J PET-CT and 18F-FE-PE2I PET-MR at baseline and after 2 years.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
50
Positron Emission Tomography (PET) of synaptic vesicle protein 2A (SV2A) using the radioligand 11C-UCB-J.
Positron Emission Tomography (PET) of dopamine transporter (DAT) using the radioligand 18F-FE-PE2I, and brain MRI performed simultaneously.
UZ Leuven
Leuven, Vlaams-Brabant, Belgium
Baseline differences in synaptic density.
Baseline differences (%) in synaptic density between patients and controls.
Time frame: Data analysis wel be done when all subjects have undergone the baseline evaluation.
Correlations between clinical scores and synaptic density.
Correlations between clinical scores and synaptic density in the patient group.
Time frame: Data analysis wel be done when all subjects have undergone the 2-year follow-up evaluation.
Differences in the rate of decline of synaptic density.
Differences (%) in the rate of decline of synaptic density between patients and controls.
Time frame: Data analysis wel be done when all subjects have undergone the 2-year follow-up evaluation.
Correlations between progression of the clinical scores and decline of synaptic density.
Correlations between progression of the clinical scores and decline of synaptic density in the patient group.
Time frame: Data analysis wel be done when all subjects have undergone the 2-year follow-up evaluation.
Baseline differences in DAT levels.
Baseline differences (%) in DAT levels between patients and controls.
Time frame: Data analysis wel be done when all subjects have undergone the baseline evaluation.
Correlations between clinical scores and DAT levels.
Correlations between clinical scores and DAT levels in the patient group.
Time frame: Data analysis wel be done when all subjects have undergone the 2-year follow-up evaluation.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Differences in the rate of decline of global and DAT levels.
Differences (%) in the rate of decline of global and DAT levels between patients and controls.
Time frame: Data analysis wel be done when all subjects have undergone the 2-year follow-up evaluation.
Correlations between progression of the clinical scores and decline of DAT levels.
Correlations between progression of the clinical scores and decline of DAT levels in the patient group.
Time frame: Data analysis wel be done when all subjects have undergone the 2-year follow-up evaluation.